# Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

Source: https://onco.cc/trials/nct07575191/  
OnCo record `nct07575191` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by Smartwise Sweden AB, now recruiting.

## Summary

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT07575191 by Smartwise Sweden AB, with 9 participants planned, started 2026-04-29 and due to reach its primary completion in 2027-12. Interventions recorded: Gemcitabine and Extroducer Infusion Catheter System.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07575191
- Phase: 1/2
- Setting: A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Unresectable Locally Advanced Pancreatic Cancer
- Sponsor: Smartwise Sweden AB
- Enrolled: 9

## Sources

- ClinicalTrials.gov NCT07575191: https://clinicaltrials.gov/study/NCT07575191

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07575191.json